Found: 7
Select item for more details and to access through your institution.
Bone protection by estrens occurs through non--tissue-selective activation of the androgen receptor.
- Published in:
- Journal of Clinical Investigation, 2006, v. 116, n. 9, p. 2500, doi. 10.1172/JCI28809
- By:
- Publication type:
- Article
Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects.
- Published in:
- British Journal of Clinical Pharmacology, 2016, v. 82, n. 1, p. 139, doi. 10.1111/bcp.12900
- By:
- Publication type:
- Article
TIF1γ, a novel member of the transcriptional intermediary factor 1 family.
- Published in:
- Oncogene, 1999, v. 18, n. 5, p. 1209, doi. 10.1038/sj.onc.1202655
- By:
- Publication type:
- Article
Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-κB site.
- Published in:
- Nucleic Acids Research, 1997, v. 25, n. 12, p. 2424, doi. 10.1093/nar/25.12.2424
- By:
- Publication type:
- Article
O02 The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile in the blood of patients with active rheumatoid arthritis.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
- Published in:
- Arthritis & Rheumatology, 2017, v. 69, n. 10, p. 1949, doi. 10.1002/art.40186
- By:
- Publication type:
- Article
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials.
- Published in:
- Rheumatology & Therapy, 2020, v. 7, n. 1, p. 173, doi. 10.1007/s40744-019-00192-5
- By:
- Publication type:
- Article